الفهرس 
Anatomy of The LiverOnly 14 pages are availabe for public view
 |  | from | 84 |  |  |
| | | from | 84 | | |
Abstract
Over the last 10 years a wide variety of clinical applications for RFA have been developed and RFA has gained clinical acceptance in many centres.
Regarding clinical and oncological prerequisites a RFneedle can be placed in a target lesion as long as the target can be displayed by US, CT, or MRI. If the RFA is performed in an adequate manner considering safety margins complete tumour destruction can be expected. At present, RFA is still limited by the suboptimal way of monitoring the procedure and the maximum size of the ablation volume that can be achieved.
Persistent fat in the ablation zone does not necessarily imply treatment failure. Moreover, changes in the size of fat content in the ablation zone could be an additional tool to determine treatment success or failure of RF ablation of fatty HCC.
CT provides a systematic evaluation of the chest and abdomen for metastatic disease and is helpful for assessing tumor response to therapy. MRI provides the most information about tumor characterization in general, and it is most helpful in distinguishing liver tumor types and in assessing tumor response.
Persistence of fat in the ablation zone during imaging follow- up after RF ablation of fat-containing HCCs does not necessarily indicate treatment failure. Changes in fat content of the ablation zone during follow-up (increase or decrease in size) could be used as additional criteria to determine success or failure of RF ablation in fat-containing HCC.
Finally, it is recommend that follow-up images after RF ablation of fat-containing HCC be regularly compared with previous images, and changes in persistent fat should be repeatedly assessed.